HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent reform

This article was originally published in The Tan Sheet

Executive Summary

House approves American Inventor's Protection Act (HR 1907) Aug. 4, providing for day-to-day restoration of patent term lost at the Patent & Trademark Office through delays in reviews, appeals and interferences. Introduced by Rep. Howard Coble (R-N.C.) May 24, the bill establishes PTO as an independent agency under the Department of Commerce and establishes two patent and trademark public advisory committees (1"The Tan Sheet" June 14, p. 12). Senate Judiciary Committee Chairman Orrin Hatch (R-Utah) is expected to consider the bill or to introduce companion legislation this autumn

You may also be interested in...



HR 1907 Would Bar Patent Reexamination Requesters From Future Challenges

Any party that requests a patent reexamination would be stopped from challenging any fact determined during that process in later civil actions under an en bloc amendment to the House patent overhaul bill (HR 1907) adopted during a recent House Judiciary Committee markup.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS140947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel